Ceftriaxone Ameliorates Motor Deficits and Protects Dopaminergic Neurons in 6-Hydroxydopamine-Lesioned Rats
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Parkinson's disease is caused by the degeneration of dopaminergic neurons in substantia nigra. There is no current promising treatment for neuroprotection of dopaminergic neurons. Ceftriaxone is a beta-lactam antibiotic and has been reported to offer neuroprotective effects (Rothstein, J.-D., Patel, S., Regan, M.-R., Haenggeli, C., Huang, Y.-H., Bergles, D.-E., Jin, L., Dykes, H.-M., Vidensky, S., Chung, D.-S., Toan, S.-V., Bruijn, L.-I., Su, Z.-Z., Gupta, P., and Fisher, P.-B. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression Nature433, 73-77). In the present study, efficacy of ceftriaxone in neuroprotection of dopaminergic neurons and amelioration of motor deficits in a rat model of Parkinson's disease were investigated. Ceftriaxone was administrated in 6-hydroxydopamine-lesioned rats. Using behavioral tests, grip strength and numbers of apomorphine-induced contralateral rotation were declined in the ceftriaxone-treated group. More importantly, cell death of dopaminergic neurons was found to decrease. In addition, both the protein expression and immunoreactivity for GLT-1 were up-regulated. The present results strongly indicate that ceftriaxone is a potential agent in the treatment of Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the neuronal level, pre- or post- treatment with CTX prevented the loss of TH-positive neurons, reduced glutamatergic hyperactivity, and promoted neurogenesis at the level of SN and hippocampal dentate gyrus in different rat models of the disease [233,237,238,239,240,241,242].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a consequence, dyskinesia, motor impairment and memory loss were all reverted upon CTX administration [233,234,237,238,239,240,242,243,244], although conflicting evidence still remains about its ability to improve learning outcomes [245].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the neuronal level, pre- or post- treatment with CTX prevented the loss of TH-positive neurons, reduced glutamatergic hyperactivity, and promoted neurogenesis at the level of SN and hippocampal dentate gyrus in different rat models of the disease [233,237,238,239,240,241,242].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
Experimental — accuracy not yet measuredIn the citing paper
“As a consequence, dyskinesia, motor impairment and memory loss were all reverted upon CTX administration [233,234,237,238,239,240,242,243,244], although conflicting evidence still remains about its ability to improve learning outcomes [245].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
In the citing paper
“At the neuronal level, pre- or post- treatment with CTX prevented the loss of TH-positive neurons, reduced glutamatergic hyperactivity, and promoted neurogenesis at the level of SN and hippocampal dentate gyrus in different rat models of the disease [233,237,238,239,240,241,242].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., Kanai, Y., Hediger, M. A., Wang, Y., Schielke, J. P., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80086-0 · Cited by 2,534
Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P. D., Benazzouz, A., LeBas, J. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035275 · Cited by 2,249
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis
Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380114 · Cited by 1,471
Perlmutter, J. S., & Mink, J. W. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112824 · Cited by 1,073
Animal models of Parkinson's disease
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2002) · BioEssays · doi:10.1002/bies.10067 · Cited by 592
Brain Glutamate Transporter Proteins Form Homomultimers
Haugeto, Ø., Ullensvang, K., Levy, L. M., Chaudhry, F. A., Honoré, T., Nielsen, M., Lehre, K. P., & Danbolt, N. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27715 · Cited by 488
Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases
Choi, J., Sullards, M. C., Olzmann, J. A., Rees, H. D., Weintraub, S. T., Bostwick, D. E., Gearing, M., Levey, A. I., Chin, L.-S., & Li, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509079200 · Cited by 483
Requena, J. R., Chao, C.-C., Levine, R. L., & Stadtman, E. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.69 · Cited by 415
Actions of TNF‐α on glutamatergic synaptic transmission in the central nervous system
Pickering, M., Cumiskey, D., & O'Connor, J. J. (2005) · Experimental Physiology · doi:10.1113/expphysiol.2005.030734 · Cited by 411
Research works printed but not linked: 2
- Paxinos G., and Watson C.. (1986)The Rat Brain in Stereotaxic Coordinates, 2nd ed., Academic Press, San Diego. [Google Scholar]
- Mandell G. L., and Sande M. A. (1990) Antimicrobial agents. In Goodman and Gilman’s The Pharmacological Basic of Therapeutics (Gilman A. G., Rall T. W., Niles A. S., and Taylor P., Eds.), pp 1085–1092, Pergamon Press, New York. [Google Scholar]
Cited by
Takahashi, K., Foster, J. B., & Lin, C.-L. G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1937-8 · Cited by 208
Neuron-Astrocyte Interactions in Parkinson’s Disease
Miyazaki, I., & Asanuma, M. (2020) · Cells · doi:10.3390/cells9122623 · Cited by 186
Current approaches to enhance glutamate transporter function and expression
Fontana, A. C. K. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13200 · Cited by 168
Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162
Clark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123
Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson’s disease model
Zhang, Y., He, X., Meng, X., Wu, X., Tong, H., Zhang, X., & Qu, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.454 · Cited by 99
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Chotibut, T., Davis, R. W., Arnold, J. C., Frenchek, Z., Gurwara, S., Bondada, V., Geddes, J. W., & Salvatore, M. F. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8598-0 · Cited by 86
Zhang, Y., Tan, F., Xu, P., & Qu, S. (2016) · Neural Plasticity · doi:10.1155/2016/8941327 · Cited by 73
Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
Yimer, E. M., Hishe, H. Z., & Tuem, K. B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00236 · Cited by 72
Ceftriaxone Blocks the Polymerization of α-Synuclein and Exerts Neuroprotective Effects in Vitro
Ruzza, P., Siligardi, G., Hussain, R., Marchiani, A., Islami, M., Bubacco, L., Delogu, G., Fabbri, D., Dettori, M. A., Sechi, M., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn400149k · Cited by 70
Smaga, I., Fierro, D., Mesa, J., Filip, M., & Knackstedt, L. A. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.05.016 · Cited by 69
Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation
Oliveri, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.045 · Cited by 68
Hsu, C.-Y., Hung, C.-S., Chang, H.-M., Liao, W.-C., Ho, S.-C., & Ho, Y.-J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.023 · Cited by 63
Bisht, R., Kaur, B., Gupta, H., & Prakash, A. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.05.009 · Cited by 62
Cordycepin mitigates MPTP-induced Parkinson's disease through inhibiting TLR/NF-κB signaling pathway
Cheng, C., & Zhu, X. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.02.037 · Cited by 59
Chotibut, T., Meadows, S., Kasanga, E. A., McInnis, T., Cantu, M. A., Bishop, C., & Salvatore, M. F. (2017) · Movement Disorders · doi:10.1002/mds.27077 · Cited by 56
Briggs, C., Hirasawa, M., & Semba, K. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2179-17.2018 · Cited by 55
Zhang, Y., Liu, Y., Kang, X.-P., Dou, C.-Y., Zhuo, R., Huang, S., Peng, L., & Wen, L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.012 · Cited by 55
Kaur, B., & Prakash, A. (2017) · Pathophysiology · doi:10.1016/j.pathophys.2017.02.001 · Cited by 54
α-Synuclein Aggregation Modulation: An Emerging Approach for the Treatment of Parkinson'S Disease
Singh, S. K., Dutta, A. K., & Modi, G. P. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0016 · Cited by 53
Pajarillo, E. A. B., Johnson, J., Rizor, A., Nyarko‐Danquah, I., Adinew, G. M., Bornhorst, J., Stiboller, M., Schwerdtle, T., Son, D., Aschner, M., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015552 · Cited by 51
Hardaway, J. A., Sturgeon, S. M., Snarrenberg, C. L., Li, Z., Xu, X. Z. S., Bermingham, D. P., Odiase, P., Spencer, W. C., Miller, D. M., Carvelli, L., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0800-15.2015 · Cited by 45
Tikhonova, M. A., Ho, S.-C., Akopyan, A. A., Kolosova, N. G., Weng, J., Meng, W.-Y., Lin, C., Amstislavskaya, T. G., & Ho, Y. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.05.002 · Cited by 44
Ceftriaxone Protects Astrocytes from MPP+ via Suppression of NF-ΚB/JNK/c-Jun Signaling
Zhang, Y., Zhang, X., & Qu, S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8845-z · Cited by 39
“Previous studies suggest that ceftriaxone is protective in PD rodent models [19, 20].”
Tikhonova, M. A., Amstislavskaya, T. G., Ho, Y., Akopyan, A. A., Tenditnik, M. V., Ovsyukova, M. V., Bashirzade, A. A., Dubrovina, N. I., & Aftanas, L. I. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.736786 · Cited by 37
Li, L., Jiang, Y., Liu, Y., Li, H., Bari, A., Ullah, R., & Xue, J. (2019) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2019.111657 · Cited by 37
Urinary Tract Infection in Parkinson’s Disease
Hogg, E., Frank, S., Oft, J., Benway, B., Rashid, M. H., & Lahiri, S. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-213103 · Cited by 37
Hsieh, M.-H., Meng, W.-Y., Liao, W.-C., Weng, J.-C., Li, H.-H., Su, H.-L., Lin, C.-L., Hung, C.-S., & Ho, Y.-J. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.05.015 · Cited by 35
Lotan, D., Cunningham, M. W., & Joel, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101257 · Cited by 34
Kelsey, J. E., & Neville, C. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3400-6 · Cited by 30
“…rather than by indirectly decreasing ongoing neurodegeneration, the fact that ceftriaxone can reduce such degeneration in animal models of PD (Leung et al. 2012) and other disorders (e.g., Rothstein et al. 2005; Chu et al. 2007; Miller et al. 2008) suggests that ceftriaxone could also reduce…”
BackgroundInfluentialPregabalin: Potential for Addiction and a Possible Glutamatergic Mechanism
Althobaiti, Y. S., Almalki, A. H., Alsaab, H. O., Alsanie, W. F., Gaber, A., Alhadidi, Q., Grégio, A. M. T., Nasr, A., Alzahrani, O., Stary, C. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51556-4 · Cited by 29
Manolaras, I., Bondio, A. D., Griso, O., Reutenauer, L., Eisenmann, A., Habermann, B. H., & Puccio, H. M. (2023) · Brain · doi:10.1093/brain/awad099 · Cited by 29
Astrocyte elevated gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND
Vartak-Sharma, N., Nooka, S., & Ghorpade, A. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.006 · Cited by 28
Too, L. K., Ball, H. J., McGregor, I. S., & Hunt, N. H. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2013.09.007 · Cited by 27
Ahanger, I. A., & Dar, T. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102538 · Cited by 27
Gibson, C. L., Balbona, J. T., Niedzwiecki, A., Rodriguez, P., Nguyen, K. C. Q., Hall, D. H., & Blakely, R. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007269 · Cited by 25
Barr, J. L., Rasmussen, B. A., Tallarida, C. S., Scholl, J. L., Forster, G. L., Unterwald, E. M., & Rawls, S. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13330 · Cited by 24
Zhong, Z., He, X., Ge, J., Zhu, J., Yao, C., Cai, H., Ye, X., Xie, T., & Bai, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114378 · Cited by 23
Ruzza, P., Vitale, R. M., Hussain, R., Biondi, B., Amodeo, P., Sechi, G., & Siligardi, G. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.04.021 · Cited by 22
Glutamic Acid Transporters: Targets for Neuroprotective Therapies in Parkinson’s Disease
Li, X., Wang, W., Yan, J., & Zeng, F. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.678154 · Cited by 22
Foster, J. B., Zhao, F., Wang, X., Xu, Z., Lin, K. J., Askwith, C. C., Hodgetts, K. J., & Lin, C. G. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.07.028 · Cited by 22
Althobaiti, Y. S., Almalki, A. H., Das, S. C., Alshehri, F. S., & Sari, Y. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.09.058 · Cited by 22
Sałat, K., Furgała, A., & Sałat, R. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.01.008 · Cited by 22
Ren, C., He, K.-J., Hu, H., Zhang, J.-B., Dong, L.-G., Li, D., Chen, J., Mao, C.-J., Wang, F., & Liu, C.-F. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212640 · Cited by 20
Sechi, G., & Sechi, M. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011198 · Cited by 20
Antibiotics acting as neuroprotectants via mechanisms independent of their anti-infective activities
Stock, M. L., Fiedler, K. J., Acharya, S., Lange, J. K., Mlynarczyk, G. S. A., Anderson, S. J., Schmidt-McCormack, G. R., Kanuri, S. H., Kondru, N. C., Brewer, M. T., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.059 · Cited by 20
Serial exposure to ethanol drinking and methamphetamine enhances glutamate excitotoxicity
Blaker, A. L., Moore, E. R., & Yamamoto, B. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14861 · Cited by 18
Modulating the Amyloidogenesis of ?-Synuclein
Sivanesam, K., & Andersen, N. H. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030103153 · Cited by 18
Yang, J., Kuo, Y., Lee, K.-C., De, S., & Chen, Y. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.214065 · Cited by 18
Gibson, C. L., Codreanu, S. G., Schrimpe‐Rutledge, A. C., Retzlaff, C. L., Wright, J., Mortlock, D. P., Sherrod, S. D., MCLEAN, J. A. J., & Blakely, R. (2018) · Molecular Omics · doi:10.1039/c7mo00022g · Cited by 17
Zeng, X., Xu, K. Y., Wang, J., Xu, Y., & Qu, S. (2020) · Neural Plasticity · doi:10.1155/2020/8872296 · Cited by 16
Rodriguez, P., Kalia, V., Fenollar‐Ferrer, C., Gibson, C. L., Gichi, Z., Rajoo, A., Matier, C. D., Pezacki, A. T., Xiao, T., Carvelli, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2320611121 · Cited by 15
Bajrektarevic, D., & Nistri, A. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.02.013 · Cited by 15
Kuo, Y., Tsai, H.-C., & Rajesh, R. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00555 · Cited by 14
Retzlaff, C. L., Kussrow, A. K., Schorkopf, T., Saetear, P., Bornhop, D. J., Hardaway, J. A., Sturgeon, S. M., Wright, J., & Blakely, R. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00232 · Cited by 13
Ceftriaxone improves senile neurocognition damages induced by D-galactose in mice.
Hakimizadeh, E., Kaeidi, A., Taghipour, Z., Mehrzadi, S., Allahtavakoli, M., Shamsizadeh, A., Bazmandegan, G., Hassanshahi, J., Aflatoonian, M. R., & Fatemi, I. (2020) · PubMed Central · doi:10.22038/ijbms.2019.40344.9556 · Cited by 13
Tolve, M., Tutas, J., Ozer, E., Klein, I., Petzold, A., Fritz, V. J., Overhoff, M., Silverman, Q., Koletsou, E., Liebsch, F., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115256 · Cited by 13
Ochoa-Aguilar, A., Sotomayor-Sobrino, M. A., Jaimez, R., Rodriguez, R. J., Plancarte, R., & Ventura‐Martínez, R. (2017) · Drug Development Research · doi:10.1002/ddr.21381 · Cited by 11
Lin, C., Zheng, T.-L., Tsou, S., Chang, H., Tseng, L., Yu, C., Hung, C., & Ho, Y. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114035 · Cited by 9
Çini, N., Atasoy, Ö., Uyanıkgil, Y., Yaprak, G., Erdoğan, M. A., & Erbaş, O. (2025) · Strahlentherapie und Onkologie · doi:10.1007/s00066-025-02405-z · Cited by 6
Zhang, Y., Zhang, X., & Qu, S. (2014) · Amino Acids · doi:10.1007/s00726-014-1731-1 · Cited by 6
Drugs to Alter Extracellular Concentration of Glutamate: Modulators of Glutamate Uptake Systems
Fontana, A. C. K. (2017) · Neuromethods · doi:10.1007/978-1-4939-7228-9_7 · Cited by 5
Partial�decortication ameliorates dopamine depletion‑induced striatal neuron lesions in rats
Zhu, Y., Liu, B., Zheng, X., Wu, J., Chen, S. X., Chen, Z., Chen, T., Huang, Z., & Lei, W. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4288 · Cited by 5
Behavioral Effects of Antibacterial Antibiotics-from Theory to Medical Practice
Nechifor, M., Luca, M. C., Galeş, C., & Rusu-Zota, G. (2023) · International Journal of Pharmacology · doi:10.3923/ijp.2023.595.603 · Cited by 4
Honisch, C., Torni, F., Hussain, R., Ruzza, P., & Siligardi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062932 · Cited by 4
NON-ANTIBIOTIC USE OF ANTIBIOTICS
Danielewski, M., Ksiądzyna, D., & Szeląg, A. (2018) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.21307/pm-2018.57.4.301 · Cited by 3
Astrocyte Glutamate Transporter EAAT2 in Alzheimer Dementia
Kurkinen, M. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_7 · Cited by 3
Management with antibiotics in Parkinson's disease
Bortolanza, M., Santos‐Lobato, B. L., Nascimento, G. C., & Bel, E. A. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815946-0.00029-6 · Cited by 2
Glutamate Transporters in Health and Disease
Reeb, K. L., Gill, S. K., Temmermand, R., & Fontana, A. C. K. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005544 · Cited by 2
Ceftriaxone Decreases MPTP-induced Behavioral Disturbances in Animal Model of Parkinson’s disease
Amiri, M., Taherian, R., Nazari, H., & Taherian, M. (2016) · International Clinical Neuroscience Journal · doi:10.22037/icnj.v3i4.14365 · Cited by 1
Wen, P., Dou, L., Yang, X., Han, D., Wang, J., 吴洪亮, & Ren, C. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s626484 · Cited by 1
Frangieh, M. R., Saad, M., Fattouh, N., & Sawan, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119903
Alzheimer’s Dementia Drug Discovery
Kurkinen, M. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00044-0
Peripheral nerve injury recovery enhanced by ceftriaxone: a preclinical investigation
Günar, B., Bora, E. S., Topkar, O. M., Baysal, Ö., Shammadli, Z., & Erbaş, O. (2025) · Acta Cirúrgica Brasileira · doi:10.1590/acb404625
Zhang, L., Song, J., Huang, J., Liang, P., Yang, H., Zhang, C., & Shen, K. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70893
Manolaras, I. (2020) · theses.fr (ABES) · doi:10.70675/3c59993cz5c5cz4b94z993ezbbe3ddeea079
Jadhav, K. S. (2014) · Journal of Pharmaceutical Research International · doi:10.9734/bjpr/2014/9473
Reeb, K. L., Gill, S. K., Hall, J. L., Poli, A. N. R., Salvino, J. M., & Fontana, A. C. K. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150560
Two Sides of the Same Coin - Neurotransmitters in Health and Disease
Fatima-Shad, K., & Heinbockel, T. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1001719
O papel dos receptores de adenosina A2A em astrócitos - implicações para a actividade glutamatérgica
Matos, M. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Development of Pyridazine-Derivatives for the Treatment of Neurological Disorders
Foster, J. B. (2019) · OhioLink ETD Center (Ohio Library and Information Network)
Sivanesam, K. (2017) · ResearchWorks at the University of Washington (University of Washington)
CEFTRIAXONE BLOCKS THE POLYMERIZATION OF Α-SYNUCLEIN AND EXERTS NEUROPROTECTIVE EFFECTS IN VITRO
Vidhya, G., Anitha, J., & Yadav, A. S. (2019) · Türk bilgisayar ve matematik eğitimi dergisi · doi:10.61841/turcomat.v10i3.14463
Tikhonova, M. A., Amstislavskaya, T. G., Ho, Y.-J., Akopyan, A. A., Tenditnik, M. V., Ovsyukova, M. V., Bashirzade, A. A., Dubrovina, N. I., & Aftanas, L. I. (2021) · doi:10.3389/fnins.2021.736786.s001
Metadata
- Authors
- Leung, T. C. H., Lui, C. N. P., Chen, L. W., Yung, W. H., Chan, Y. S., & Yung, K. K. L.
- Affiliations
- Hong Kong Baptist University (HK)
- Air Force Medical University (CN)
- Chinese University of Hong Kong (HK)
- University of Hong Kong (HK)
- Corresponding author
- Yung, K. K. L.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-11-04
- Volume
- 3
- Issue
- 1
- Pages
- 22-30
- ISSN
- 1948-7193 (ISSN-L)
- PMC
- PMC3369786
- OpenAlex
- W2024142654
- Cited by
- 78
- References
- 40
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 6 · 2017: 11 · 2016: 6 · 2015: 5 · 2014: 7 · 2013: 4
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HKBU Institutional Repository (Hong Kong Baptist University) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- ceftriaxone, Parkinson's disease, neuroprotection, dopaminergic neurons, substantia nigra, 6-hydroxydopamine lesion, motor impairment, GLT-1, glutamate transporters, beta-lactam antibiotics, cell death
- MeSH terms
- Animals, Behavior, Animal, Brain, Ceftriaxone, Female, Motor Activity, Blotting, Western, Oxidopamine, Rats, Sprague-Dawley, Neuroprotective Agents, Parkinsonian Disorders, Rats, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.